The continuum of high ovarian response: a rational approach to the management of high responder patient subgroups

References

• Abdallah, R., Kligman, I., Davis, O. and Rosenwaks, Z. (2010) Withholding gonadotropins until human chorionic gonadotropin administration. Semin Reprod Med 28:486–492
   PubMed Web of Science ®Google Scholar
• Aboulghar, M.A., Mansour, R.T., Amin, Y.M., Al-Inany, H.G., Aboulghar, M.M. and Serour, G.I. (2007) A prospective randomized study comparing coasting with GnRH antagonist administration in patients at risk for severe OHSS. Reprod Biomed Online 15:271–279
   PubMed Web of Science ®Google Scholar
• Acevedo, B., Gomez-Palomares, J.L., Ricciarelli, E. and Hernandez, E.R. (2006) Triggering ovulation with gonadotropin-releasing hormone agonists does not compromise embryo implantation rates. Fertil Steril 86:1682–1687
   PubMed Web of Science ®Google Scholar
• Alvarez, C., Marti-Bonmati, L., Novella-Maestre, E., Sanz, R., Gomez, R., Fernandez-Sanchez, M., et al. (2007) Dopamine agonist cabergoline reduces hemoconcentration and ascites in hyperstimulated women undergoing assisted reproduction. J Clin Endocrinol Metab 92:2931–2937
   PubMed Web of Science ®Google Scholar
• Amso, N.N., Ahuja, K.K., Morris, N. and Shaw, R.W. (1990) The management of predicted ovarian hyperstimulation involving gonadotropin-releasing hormone analog with elective cryopreservation of all pre-embryos. Fertil Steril 53:1087–1090
   PubMed Web of Science ®Google Scholar
• Arce, J.C., Andersen, A.N., Fernandez-Sanchez, M., Visnova, H., Bosch, E., Garcia-Velasco, J.A., et al. (2014) Ovarian response to recombinant human follicle-stimulating hormone: a randomized, antimullerian hormone-stratified, dose-response trial in women undergoing in vitro fertilization/intracytoplasmic sperm injection. Fertil Steril 102:1633–1640 e1635
   PubMed Web of Science ®Google Scholar
• Broekmans, F.J., Verweij, P.J., Eijkemans, M.J., Mannaerts, B.M. and Witjes, H. (2014) Prognostic models for high and low ovarian responses in controlled ovarian stimulation using a GnRH antagonist protocol. Hum Reprod 29:1688–1697
   PubMed Web of Science ®Google Scholar
• Broer, S.L., Mol, B.W., Hendriks, D. and Broekmans, F.J. (2009) The role of antimullerian hormone in prediction of outcome after IVF: comparison with the antral follicle count. Fertil Steril 91:705–714
   PubMed Web of Science ®Google Scholar
• Casano, S., Guidetti, D., Patriarca, A., Pittatore, G., Gennarelli, G. and Revelli, A. (2012) MILD ovarian stimulation with GnRH-antagonist vs. long protocol with low dose FSH for non-PCO high responders undergoing IVF: a prospective, randomized study including thawing cycles. J Assist Reprod Genet 29:1343–1351
   PubMed Web of Science ®Google Scholar
• Child, T.J., Abdul-Jalil, A.K., Gulekli, B. and Tan, S.L. (2001) In vitro maturation and fertilization of oocytes from unstimulated normal ovaries, polycystic ovaries, and women with polycystic ovary syndrome. Fertil Steril 76:936–942
   PubMed Web of Science ®Google Scholar
• D'Angelo, A. (2010) Ovarian hyperstimulation syndrome prevention strategies: cryopreservation of all embryos. Semin Reprod Med 28:513–518
   PubMed Web of Science ®Google Scholar
• D'Angelo, A., Brown, J. and Amso, N.N. (2011) Coasting (withholding gonadotrophins) for preventing ovarian hyperstimulation syndrome. Cochrane Database Syst Rev 15:CD002811
   Google Scholar
• Damario, M.A. (2010) Ovarian hyperstimulation syndrome prevention strategies: oral contraceptive pills-dual gonadotropin-releasing hormone agonist suppression with step-down gonadotropin protocols. Semin Reprod Med 28:468–474
   PubMed Web of Science ®Google Scholar
• Datta, A.K., Eapen, A., Birch, H., Kurinchi-Selvan, A. and Lockwood, G. (2014) Retrospective comparison of GnRH agonist trigger with HCG trigger in GnRH antagonist cycles in anticipated high-responders. Reprod Biomed Online 29:552–558
   PubMed Web of Science ®Google Scholar
• Delvigne, A. and Rozenberg, S. (2002) Epidemiology and prevention of ovarian hyperstimulation syndrome (OHSS): a review. Hum Reprod Update 8:559–577
   PubMed Web of Science ®Google Scholar
• Devroey, P., Polyzos, N.P. and Blockeel, C. (2011) An OHSS-Free Clinic by segmentation of IVF treatment. Hum Reprod 26:2593–2597
   PubMed Web of Science ®Google Scholar
• Engmann, L. and Benadiva, C. (2012) Agonist trigger: what is the best approach? Agonist trigger with aggressive luteal support. Fertil Steril 97:531–533
   PubMed Web of Science ®Google Scholar
• Engmann, L., DiLuigi, A., Schmidt, D., Nulsen, J., Maier, D. and Benadiva, C. (2008) The use of gonadotropin-releasing hormone (GnRH) agonist to induce oocyte maturation after cotreatment with GnRH antagonist in high-risk patients undergoing in vitro fertilization prevents the risk of ovarian hyperstimulation syndrome: a prospective randomized controlled study. Fertil Steril 89:84–91
   PubMed Web of Science ®Google Scholar
• Evans, J., Hannan, N.J., Edgell, T.A., Vollenhoven, B.J., Lutjen, P.J., Osianlis, T., et al. (2014) Fresh versus frozen embryo transfer: backing clinical decisions with scientific and clinical evidence. Hum Reprod Update 20:808–821
   PubMed Web of Science ®Google Scholar
• Fadini, R., Mignini Renzini, M., Dal Canto, M., Epis, A., Crippa, M., Caliari, I., et al. (2013) Oocyte in vitro maturation in normo-ovulatory women. Fertil Steril 99:1162–1169
   PubMed Web of Science ®Google Scholar
• Fatemi, H.M., Popovic-Todorovic, B., Humaidan, P., Kol, S., Banker, M., Devroey, P., et al. (2014) Severe ovarian hyperstimulation syndrome after gonadotropin-releasing hormone (GnRH) agonist trigger and “freeze-all” approach in GnRH antagonist protocol. Fertil Steril 101:1008–1011
   PubMed Web of Science ®Google Scholar
• Fauser, B.C., de Jong, D., Olivennes, F., Wramsby, H., Tay, C., Itskovitz-Eldor, J., et al. (2002) Endocrine profiles after triggering of final oocyte maturation with GnRH agonist after cotreatment with the GnRH antagonist ganirelix during ovarian hyperstimulation for in vitro fertilization. J Clin Endocrinol Metab 87:709–715
   PubMed Web of Science ®Google Scholar
• Ferraretti, A.P., La Marca, A., Fauser, B.C., Tarlatzis, B., Nargund, G., Gianaroli, L., et al. (2011) ESHRE consensus on the definition of ‘poor response' to ovarian stimulation for in vitro fertilization: the Bologna criteria. Hum Reprod 26:1616–1624
   PubMed Web of Science ®Google Scholar
• Fluker, M.R., Hooper, W.M. and Yuzpe, A.A. (1999) Withholding gonadotropins (“coasting”) to minimize the risk of ovarian hyperstimulation during superovulation and in vitro fertilization-embryo transfer cycles. Fertil Steril 71:294–301
   PubMed Web of Science ®Google Scholar
• Garcia, J.E., Jones, G.S., Acosta, A.A. and Wright, G Jr. (1983) Human menopausal gonadotropin/human chorionic gonadotropin follicular maturation for oocyte aspiration: phase II, 1981. Fertil Steril 39:174–179
   PubMed Web of Science ®Google Scholar
• Gomez, R., Soares, S.R., Busso, C., Garcia-Velasco, J.A., Simon, C. and Pellicer, A. (2010) Physiology and pathology of ovarian hyperstimulation syndrome. Semin Reprod Med 28:448–457
   PubMed Web of Science ®Google Scholar
• Gonen, Y., Balakier, H., Powell, W. and Casper, R.F. (1990) Use of gonadotropin-releasing hormone agonist to trigger follicular maturation for in vitro fertilization. J Clin Endocrinol Metab 71:918–922
   PubMed Web of Science ®Google Scholar
• Griffin, D., Benadiva, C., Kummer, N., Budinetz, T., Nulsen, J. and Engmann, L. (2012) Dual trigger of oocyte maturation with gonadotropin-releasing hormone agonist and low-dose human chorionic gonadotropin to optimize live birth rates in high responders. Fertil Steril 97:1316–1320
   PubMed Web of Science ®Google Scholar
• Griffin, D., Feinn, R., Engmann, L., Nulsen, J., Budinetz, T. and Benadiva, C. (2014) Dual trigger with gonadotropin-releasing hormone agonist and standard dose human chorionic gonadotropin to improve oocyte maturity rates. Fertil Steril 102:405–409
   PubMed Web of Science ®Google Scholar
• Haas, J., Zilberberg, E., Dar, S., Kedem, A., Machtinger, R. and Orvieto, R. (2014) Co-administration of GnRH-agonist and hCG for final oocyte maturation (double trigger) in patients with low number of oocytes retrieved per number of preovulatory follicles-a preliminary report. J Ovarian Res 7:77
   PubMed Web of Science ®Google Scholar
• Hamdine, O., Eijkemans, M.J., Lentjes, E.W., Torrance, H.L., Macklon, N.S., Fauser, B.C., et al. (2015) Ovarian response prediction in GnRH antagonist treatment for IVF using anti-Mullerian hormone. Hum Reprod 30:170–180
   PubMed Web of Science ®Google Scholar
• Huang, J.Y., Chian, R.C. and Tan, S.L. (2010) Ovarian hyperstimulation syndrome prevention strategies: in vitro maturation. Semin Reprod Med 28:519–531
   PubMed Web of Science ®Google Scholar
• Huber, M., Hadziosmanovic, N., Berglund, L. and Holte, J. (2013) Using the ovarian sensitivity index to define poor, normal, and high response after controlled ovarian hyperstimulation in the long gonadotropin-releasing hormone-agonist protocol: suggestions for a new principle to solve an old problem. Fertil Steril 100:1270–1276
   PubMed Web of Science ®Google Scholar
• Humaidan, P. (2009) Luteal phase rescue in high-risk OHSS patients by GnRHa triggering in combination with low-dose HCG: a pilot study. Reprod Biomed Online 18:630–634
   PubMed Web of Science ®Google Scholar
• Humaidan, P., Bredkjaer, H.E., Bungum, L., Bungum, M., Grondahl, M.L., Westergaard, L., et al. (2005) GnRH agonist (buserelin) or hCG for ovulation induction in GnRH antagonist IVF/ICSI cycles: a prospective randomized study. Hum Reprod 20:1213–1220
   PubMed Web of Science ®Google Scholar
• Humaidan, P., Ejdrup Bredkjaer, H., Westergaard, L.G. and Yding Andersen, C. (2010a) 1,500 IU human chorionic gonadotropin administered at oocyte retrieval rescues the luteal phase when gonadotropin-releasing hormone agonist is used for ovulation induction: a prospective, randomized, controlled study. Fertil Steril 93:847–854
   PubMed Web of Science ®Google Scholar
• Humaidan, P., Engmann, L. and Benadiva, C. (2015) Luteal phase supplementation after gonadotropin-releasing hormone agonist trigger in fresh embryo transfer: the American versus European approaches. Fertil Steril 103:879–885
   PubMed Web of Science ®Google Scholar
• Humaidan, P., Kol, S., Papanikolaou, E.G. and Copenhagen GnRH Agonist Triggering Workshop Group (2011) GnRH agonist for triggering of final oocyte maturation: time for a change of practice? Hum Reprod Update 17:510–524
   PubMed Web of Science ®Google Scholar
• Humaidan, P. and Polyzos, N.P. (2014) Human chorionic gonadotropin vs. gonadotropin-releasing hormone agonist trigger in assisted reproductive technology- “the king is dead, long live the king!”. Fertil Steril 102:339–341
   PubMed Web of Science ®Google Scholar
• Humaidan, P., Polyzos, N.P., Alsbjerg, B., Erb, K., Mikkelsen, A.L., Elbaek, H.O., et al. (2013) GnRHa trigger and individualized luteal phase hCG support according to ovarian response to stimulation: two prospective randomized controlled multi-centre studies in IVF patients. Hum Reprod 28:2511–2521
   PubMed Web of Science ®Google Scholar
• Humaidan, P., Quartarolo, J. and Papanikolaou, E.G. (2010b) Preventing ovarian hyperstimulation syndrome: guidance for the clinician. Fertil Steril 94:389–400
   PubMed Web of Science ®Google Scholar
• Iliodromiti, S., Blockeel, C., Tremellen, K.P., Fleming, R., Tournaye, H., Humaidan, P., et al. (2013) Consistent high clinical pregnancy rates and low ovarian hyperstimulation syndrome rates in high-risk patients after GnRH agonist triggering and modified luteal support: a retrospective multicentre study. Hum Reprod 28:2529–2536
   PubMed Web of Science ®Google Scholar
• Kolibianakis, E.M., Schultze-Mosgau, A., Schroer, A., van Steirteghem, A., Devroey, P., Diedrich, K., et al. (2005) A lower ongoing pregnancy rate can be expected when GnRH agonist is used for triggering final oocyte maturation instead of HCG in patients undergoing IVF with GnRH antagonists. Hum Reprod 20:2887–2892
   PubMed Web of Science ®Google Scholar
• Kummer, N., Benadiva, C., Feinn, R., Mann, J., Nulsen, J. and Engmann, L. (2011) Factors that predict the probability of a successful clinical outcome after induction of oocyte maturation with a gonadotropin-releasing hormone agonist. Fertil Steril 96:63–68
   PubMed Web of Science ®Google Scholar
• Lainas, T.G., Sfontouris, I.A., Papanikolaou, E.G., Zorzovilis, J.Z., Petsas, G.K., Lainas, G.T., et al. (2008) Flexible GnRH antagonist versus flare-up GnRH agonist protocol in poor responders treated by IVF: a randomized controlled trial. Hum Reprod 23:1355–1358
   PubMed Web of Science ®Google Scholar
• Lee, T.H., Liu, C.H., Huang, C.C., Wu, Y.L., Shih, Y.T., Ho, H.N., et al. (2008) Serum anti-Mullerian hormone and estradiol levels as predictors of ovarian hyperstimulation syndrome in assisted reproduction technology cycles. Hum Reprod 23:160–167
   PubMed Web of Science ®Google Scholar
• Lin, M.H., Wu, F.S., Lee, R.K., Li, S.H., Lin, S.Y. and Hwu, Y.M. (2013) Dual trigger with combination of gonadotropin-releasing hormone agonist and human chorionic gonadotropin significantly improves the live-birth rate for normal responders in GnRH-antagonist cycles. Fertil Steril 100:1296–1302
   PubMed Web of Science ®Google Scholar
• Mathur, R.S., Akande, A.V., Keay, S.D., Hunt, L.P. and Jenkins, J.M. (2000) Distinction between early and late ovarian hyperstimulation syndrome. Fertil Steril 73:901–907
   PubMed Web of Science ®Google Scholar
• Nastri, C.O., Teixeira, D.M., Moroni, R.M., Leitao, V.M. and Martins, W.P. (2015) Ovarian hyperstimulation syndrome: physiopathology, staging, prediction and prevention. Ultrasound Obstet Gynecol 45:377–393
   PubMed Web of Science ®Google Scholar
• Navot, D., Bergh, P.A. and Laufer, N. (1992) Ovarian hyperstimulation syndrome in novel reproductive technologies: prevention and treatment. Fertil Steril 58:249–261
   PubMed Web of Science ®Google Scholar
• Nelson, S.M., Yates, R.W., Lyall, H., Jamieson, M., Traynor, I., Gaudoin, M., et al. (2009) Anti-Mullerian hormone-based approach to controlled ovarian stimulation for assisted conception. Hum Reprod 24:867–875
   PubMed Web of Science ®Google Scholar
• Olivennes, F. (2010) Ovarian hyperstimulation syndrome prevention strategies: individualizing gonadotropin dose. Semin Reprod Med 28:463–467
   PubMed Web of Science ®Google Scholar
• Olivennes, F., Howles, C.M., Borini, A., Germond, M., Trew, G., Wikland, M., et al. (2009) Individualizing FSH dose for assisted reproduction using a novel algorithm: the CONSORT study. Reprod Biomed Online 18:195–204
   PubMed Web of Science ®Google Scholar
• Orvieto, R. and Homburg, R. (2009) Chronic ultra-low dose follicle-stimulating hormone regimen for patients with polycystic ovary syndrome: one click, one follicle, one pregnancy. Fertil Steril 91:1533–1535
   PubMed Web of Science ®Google Scholar
• Papanikolaou, E.G., Humaidan, P., Polyzos, N.P. and Tarlatzis, B. (2010) Identification of the high-risk patient for ovarian hyperstimulation syndrome. Semin Reprod Med 28:458–462
   PubMed Web of Science ®Google Scholar
• Papanikolaou, E.G., Pozzobon, C., Kolibianakis, E.M., Camus, M., Tournaye, H., Fatemi, H.M., et al. (2006) Incidence and prediction of ovarian hyperstimulation syndrome in women undergoing gonadotropin-releasing hormone antagonist in vitro fertilization cycles. Fertil Steril 85:112–120
   PubMed Web of Science ®Google Scholar
• Popovic-Todorovic, B., Loft, A., Bredkjaeer, H.E., Bangsboll, S., Nielsen, I.K. and Andersen, A.N. (2003) A prospective randomized clinical trial comparing an individual dose of recombinant FSH based on predictive factors versus a ‘standard' dose of 150 IU/day in ‘standard' patients undergoing IVF/ICSI treatment. Hum Reprod 18:2275–2282
   PubMed Web of Science ®Google Scholar
• Popovic-Todorovic, B., Loft, A., Ziebe, S. and Andersen, A.N. (2004) Impact of recombinant FSH dose adjustments on ovarian response in the second treatment cycle with IVF or ICSI in “standard” patients treated with 150 IU/day during the first cycle. Acta Obstet Gynecol Scand 83:842–849
   PubMed Web of Science ®Google Scholar
• Radesic, B. and Tremellen, K. (2011) Oocyte maturation employing a GnRH agonist in combination with low-dose hCG luteal rescue minimizes the severity of ovarian hyperstimulation syndrome while maintaining excellent pregnancy rates. Hum Reprod 26:3437–3442
   PubMed Web of Science ®Google Scholar
• Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group (2004) Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 81:19–25
   Web of Science ®Google Scholar
• Seyhan, A., Ata, B., Polat, M., Son, W.Y., Yarali, H. and Dahan, M.H. (2013) Severe early ovarian hyperstimulation syndrome following GnRH agonist trigger with the addition of 1500 IU hCG. Hum Reprod 28:2522–2528
   PubMed Web of Science ®Google Scholar
• Shapiro, B.S., Daneshmand, S.T., Garner, F.C., Aguirre, M. and Hudson, C. (2011) Comparison of “triggers” using leuprolide acetate alone or in combination with low-dose human chorionic gonadotropin. Fertil Steril 95:2715–2717
   PubMed Web of Science ®Google Scholar
• Shapiro, B.S., Daneshmand, S.T., Garner, F.C., Aguirre, M. and Thomas, S. (2008) Gonadotropin-releasing hormone agonist combined with a reduced dose of human chorionic gonadotropin for final oocyte maturation in fresh autologous cycles of in vitro fertilization. Fertil Steril 90:231–233
   PubMed Web of Science ®Google Scholar
• Sills, E.S., Alper, M.M. and Walsh, A.P. (2009) Ovarian reserve screening in infertility: practical applications and theoretical directions for research. Eur J Obstet Gynecol Reprod Biol 146:30–36
   PubMed Web of Science ®Google Scholar
• Siristatidis, C.S., Vrachnis, N., Creatsa, M., Maheshwari, A. and Bhattacharya, S. (2013) In vitro maturation in subfertile women with polycystic ovarian syndrome undergoing assisted reproduction. Cochrane Database Syst Rev 10:CD006606
   PubMed Web of Science ®Google Scholar
• Tarlatzis, B.C., Zepiridis, L., Grimbizis, G. and Bontis, J. (2003) Clinical management of low ovarian response to stimulation for IVF: a systematic review. Hum Reprod Update 9:61–76
   PubMed Web of Science ®Google Scholar
• Tozer, A.J., Iles, R.K., Iammarrone, E., Gillott, C.M., Al-Shawaf, T. and Grudzinskas, J.G. (2004) The effects of ‘coasting' on follicular fluid concentrations of vascular endothelial growth factor in women at risk of developing ovarian hyperstimulation syndrome. Hum Reprod 19:522–528
   PubMed Web of Science ®Google Scholar
• Tremellen, K. and Savulescu, J. (2014) Ovarian reserve screening: a scientific and ethical analysis. Hum Reprod 29:2606–2614
   PubMed Web of Science ®Google Scholar
• Wu, K.L., Zhao, H.B., Liu, H., Zhong, W.X., Yu, G.L. and Chen, Z.J. (2013) Elective single blastocyst transfer is more suitable for normal responders than for high responders. Chin Med J (Engl) 126:2125–2128
   PubMed Web of Science ®Google Scholar
• Youssef, M.A., Van der Veen, F., Al-Inany, H.G., Mochtar, M.H., Griesinger, G., Nagi Mohesen, M., et al. (2014) Gonadotropin-releasing hormone agonist versus HCG for oocyte triggering in antagonist-assisted reproductive technology. Cochrane Database Syst Rev 10:CD008046
   PubMed Web of Science ®Google Scholar
• Zivi, E., Simon, A. and Laufer, N. (2010) Ovarian hyperstimulation syndrome: definition, incidence, and classification. Semin Reprod Med 28:441–447
   PubMed Web of Science ®Google Scholar